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and no change to modest improvement from admission
to follow-up (0–1 points). CONCLUSIONS: Antidepres-
sant agents in this analysis were associated with modest
improvement in maladaptive behavior as assessed by the
PDGRS. New treatment modalities that improve mal-
adaptive behavior along with depressive symptomatology
in older patients would be beneficial. Further controlled
studies are needed to better understand these findings.
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OBJECTIVES: An array of antidepressant agents are
available in the treatment of geropsychiatric patients with
depression. While most current agents, such as the selec-
tive serotonin reuptake inhibitors (SSRI’s) (e.g., fluoxe-
tine; sertraline) and agents acting upon both serotonin
and norepinephrine (e.g., mirtazapine; venlaxafine), are
reasonably effective in ameliorating depressive symptom-
atology, less is known about the impact of these agents
on other common areas of deficit in older depressed pa-
tients, such as cognition. This study examines change in
cognitive functioning in geropsychiatric patients (age 55
and older) with major depression (ICD-9-CM codes
296.20-296.36) treated with fluoxetine (n  269), mir-
tazapine (n  275), sertraline (n  713), or venlaxafine
(n  259). METHODS: Data were obtained from the
CQISM Outcomes Measurement System, a Joint Com-
mission of Accredited Hospital Organizations (JCAHO)
ORYX accepted performance improvement system,
which tracked patients admitted to geropsychiatric inpa-
tient programs in 111 general hospitals across 33 states
between 1997–1999. Cognitive functioning was mea-
sured at admission and discharge using the Mini-Mental
State Examination (MMSE) (Folstein, Folstein, & McHugh,
1975). A Medication Usage Questionnaire was used to
track medications prescribed to patients just prior to ad-
mission and at discharge. One-way Analyses of Variance
and if significant, Tukey’s pairwise comparisons, were
used to compare medication groups. RESULTS: At ad-
mission, patients exhibited moderate evidence of cogni-
tive impairment (Mean MMSE score of 21 out of 30).
Medication groups were indistinguishable on change
scores in cognitive functioning from time of admission to
discharge (average length of stay around 16 days). The
average change score on the MMSE was 1.1 to 1.6 points,
suggesting very mild improvement. CONCLUSIONS: Anti-
depressant agents in this analysis were associated with
modest improvement in cognitive functioning as assessed
by the MMSE. New treatment modalities that improve
cognition along with depressive symptomatology in older
patients would be beneficial.
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OBJECTIVES: To compare the change in health care uti-
lization and costs from one year before (preperiod) and
one year after (postperiod) starting treatment with ris-
peridone or olanzapine in schizophrenia patients in a
Veterans Administration population. METHODS: Pa-
tients with a diagnosis of schizophrenia (ICD-9 CM code
295) in the preperiod, who had an initial prescription for
risperidone or olanzapine dispensed between 3/97 and
3/99, were included. Patients who received any atypical
antipsychotic in the preperiod were excluded. Compari-
sons of average change in utilization and cost from the
preperiod to the postperiod were made between the
groups for: inpatient hospitalizations, outpatient clinic
visits, medications, and total health care cost. Analysis of
covariance was used to analyze the data using age, gen-
der, and race as covariates. RESULTS: 304 patients in
the olanzapine group and 344 in the risperidone group
were included. The olanzapine group had significantly
more inpatient admissions per patient (0.09 vs. 0.24,
p  0.026), longer inpatient lengths of stay (4.3 days
vs. 4.2 days, p  0.004), and higher cost of inpatient
admissions ($2735 vs. $3226, p  0.003) than the ris-
peridone group. There was a significantly lower cost of
antipsychotic for the risperidone group than for the olan-
zapine group ($650 vs. $1660, p  0.001). The mean
daily doses were 3.4 mg of risperidone and 12.0 mg of
olanzapine. The olanzapine group also had a significantly
higher change in cost for all drugs ($1492 vs. $683, p 
0.001) and all health care costs ($5,665 vs. $1,167, p 
0.001) than the risperidone group. CONCLUSIONS:
The changes in total health care costs, number, length of
stay, and cost of inpatient admissions, and medication
costs for risperidone-treated patients were significantly
lower compared with olanzapine-treated patients.
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OBJECTIVES: Attention-deficit/hyperactivity disorder
(ADHD) is the most commonly diagnosed psychiatric
disorder among children in the US. However, the social
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and economic costs of ADHD are not well understood.
We sought to examine the impact of childhood ADHD
on caregivers’ work status and work productivity, and
patients’ health care use. METHODS: We conducted a
telephone survey of 154 caregivers of ADHD-diagnosed
children. Caregivers were identified from membership in
CHADD (Children and Adults with Attention-Deficit/
Hyperactivity Disorder). RESULTS: The mean number
of ADHD-diagnosed children per caregiver was 1.3
(range 1–4); 60% of children were in 6th grade or lower.
The reported mean number of prior year ADHD-related
visits to pediatricians, psychiatrists, psychologists, and
counselors was 2.0, 3.7, 2.9, and 6.6 visits, respectively.
In the 3 months prior to telephone survey, 18% of visits
were for unscheduled emergencies—63% of caregivers
reported some change in their work status as a result of
their child’s ADHD. Of these, 15% changed type of job,
46% reduced hours worked per week, and 11% stopped
working completely. During the 4 weeks prior to survey,
caregivers reported having lost an average of 0.8 days
from work and being 25% less productive, for an average
of 2.4 days attributed to their child’s ADHD—this is
equivalent to 39 days reduced caregiver productivity per
year. CONCLUSIONS: Childhood ADHD adversely af-
fects caregiver work status and work productivity.
ADHD also results in frequent unscheduled emergency
visits. Effective disease management of childhood ADHD
may ultimately mitigate substantial costs borne by em-
ployers and health care systems.
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OBJECTIVE: To examine the impact of clinical syn-
drome, type of medication and adherence on outpatient
utilization. METHODS: Baseline data predicted 6-month
outpatient utilization (n  985). Psychotherapy, clinic
visits (specimen collection), and total number of outpa-
tient visits were examined. Presence of medication (15
first-generation; 5 novel; both) was coded. Adherence re-
flected the 4-weeks prior to assessment. Clinical syn-
drome variables: deficit, hallucinations/delusions, and
disorganization. Negative binomial regression (adjusted
standard errors). RESULTS: Psychotherapy Visits: Posi-
tive effect observed for higher hallucinations/delusions
and use of both first- and second-generations. Clinic Vis-
its: The probability of visit was positively impacted by
higher disorganization, adherence, education less than
high school graduation, and CHAMPUS. Negative effect
noted for use of novel agents and having Medicare only.
Number of visits higher for those with higher disorgani-
zation. Total Outpatient Visits: Positive effect observed
for adherence at both periods and treatment with novel
agents alone or in combination with first-generation
agents. The clinical syndrome variables did not achieve
significance. CONCLUSIONS: The positive correlation
of medication adherence at both baseline and 6 months
with clinic visits and total visits is an important driver in
outpatient services utilization. The type of medication
positively impacts the number of visits, however, a nega-
tive association was observed between type of medication
and the probability of a clinic visit. It may be possible
that some persons using novel agents achieve improve-
ment through outpatient medication management (psy-
chotherapy visits) and may require less frequent clinic
visits (for specimen collection), suggesting that the favor-
able adverse event profile of second-generation agents
may promote community functioning. Positive symptoms
and disorganization drive the occurrence and number of
visits while the presence of deficit syndrome did not
achieve significance. These findings suggest that as treat-
ment costs vary by method, payers could benefit by as-
sessing clinical syndrome in order to estimate disease-
related payments accurately.
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OBJECTIVE: To examine the distribution of mental
health conditions comorbid to depression, especially anx-
iety, among patients treated for 1–6 months or 7–12
months with an SSRI. METHODS: The study comprised
a retrospective review of integrated medical and phar-
macy claims from a national managed care organization.
Continuously enrolled patients between the ages of 18
and 65 years were identified from the 1.9M claims under-
lying six IPA model plans for 1997–1998. Patients placed
on SSRI therapy following a 4 month period without
drugs were stratified according to underlying mental
health conditions and length of SSRI monotherapy. RE-
SULTS: Overall, between 47% and 52% of patients
placed on SSRI monotherapy had a history of depression;
an additional 5–12% had histories of anxiety without de-
pression. Greater proportions of patients for whom par-
oxetine was prescribed rather than either fluoxetine or
sertraline had anxiety comorbid to depression in the year
prior to initiating drug therapy(11.5%, 6.5%, 7.9%, re-
spectively)(Chi-square .001). The 40 or more percent of
patients without depression or anxiety in their histories—
12 months preceding initiation of drug therapy and
month of initiation—but treated with SSRIs often had di-
agnoses for other mental health conditions, specifically
neurotic disorders, affective psychoses, nondependent
abuse of drugs and adjustment reaction. These diagnoses
patterns persisted when patients were subset according to
persistence of therapy, i.e., SSRI therapy for greater or
